NAD Supplementation and Vascular Health in PAD

Plain-language guide to NCT06534944: phase 1, phase 2 interventional trial of NAD+, 8 participants. Who took part, design and what was measured.

Key Facts

Registry ID: NCT06534944
Phase: phase 1, phase 2
Status: completed
Start: 2023-02-27
Completion (planned or actual): 2024-07-30
Participants: 8 (actual)
Design: na, open label (everyone knows who gets what), basic_science
Conditions studied: Peripheral Artery Disease
Results posted: not yet

What This Study Did, in Plain Language

What Was Tested

The trial (phase 1, phase 2) is built around NAD+.

It had 1 arm (groups): NR supplementation (experimental).

The registry classes the interventions as drug.

More on the Plan

Peripheral artery disease (PAD) is a prevalent age-related vascular pathology and the third leading cause of cardiovascular morbidity and mortality among older adults.

One of the mechanisms that contributes to vascular dysfunction in aging and age-related diseases is the decline in the Nicotinamide Adenine Dinucleotide (NAD) levels.

Who Took Part

8 actual participants took part.

It was open to people of any sex aged from 55 years up to 99 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Diagnosis of PAD. Limited walking capacity.

The full record lists 3 inclusion and 4 exclusion criteria; among the exclusions: macologically uncontrolled type 2 diabetes, hypercholesterolemia, hypertension; major depressive disorder; current or prior cerebrovascular complications (including large vessel ischemic stroke with chronic functional impairment).

How the Study Was Run

It was run as a single-group and open-label study.

Nothing was hidden in this open-label NAD+ study: the participants and staff both knew the treatment.

Everyone received the same intervention, so there was no separate comparison group inside the trial.

It started in 2023-02-27 with completion listed for 2024-07-30.

It ran at 1 site in United States.

Its stated primary purpose is basic science.

What Was Measured

Researchers chose this as the main measure: Change in neurovascular coupling using functional near infrared spectroscopy (fNIRS) (time frame: 4 weeks). Change in macrovascular endothelial function (time frame: 4 weeks). Change in Attention (time frame: 4 weeks).

What This Means in Plain Language

Put simply, this is a phase 1, phase 2 trial of NAD+ in 8 people.

Its size is small, so on its own it can only give an early look.

The trial is marked completed; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the NAD+ compound page, all human trials.

Our Notes on the Compound

NAD+: The coenzyme that accepts electrons at complex I.

NAD+ in the library

Source: ClinicalTrials.gov record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.